Immunovia AB was founded in 2007 by scientists from the Department of Immunotechnology at Lund University and CREATE Health - A Strategic Centre for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray, is based on antibody microarray analysis. The company now performs clinical validation studies for commercialization of IMMray PanCan-d, which has the potential to become the first blood-based test for early diagnosis of cancer of the pancreas. In December 2015, the largest diagnostic retrospective study with 1400 blood samples, showed that IMMray PanCan-d is able to detect 98% of pancreatic cancers. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation.
You can find more information about Immunovia at our website, www.immunovia.com.